| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Mayo Clinic, Jacksonville, Florida, USA
Correspondence: Betty A. Mincey, M.D., Senior Associate Consultant, Mayo Clinic, General Internal Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA. Telephone: 904-953-2160; Fax: 904-953-2898; e-mail: mincey.betty{at}mayo.edu
It is estimated that 5%10% of all breast cancers in women are associated with hereditary susceptibility due to mutations in autosomal dominant genes, such as BRCA1 and BRCA2, p53, pTEN, and STK11/LKB1. Another 15%20% of female breast cancers occur in women with a family history but without an apparent autosomal dominant inheritance pattern, and are probably due to other genetic factors with environmental influence. Approximately 7%10% of ovarian cancers occur in women with hereditary susceptibility, primarily secondary to mutations in BRCA1 and BRCA2, with smaller contributions from mutations in mismatch repair genes associated with the hereditary nonpolyposis colorectal cancer and other, as yet undiscovered, genes.
This article has been cited by other articles:
![]() |
A. M. Gonzalez-Zuloeta Ladd, A. Arias Vasquez, F. A. Sayed-Tabatabaei, J.W. Coebergh, A. Hofman, O. Njajou, B. Stricker, and C. van Duijn Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2143 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Jiang, N. P. Caraway, B. Nebiyou Bekele, H.-Z. Zhang, A. Khanna, H. Wang, R. Li, R. L. Fernandez, T. M. Zaidi, D. A. Johnston, et al. Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5417 - 5424. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Reuland, A. Humeny, A. Magener, C.-M. Becker, and K. Schiebel Detection of Loss of Heterozygosity by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry-Based Analysis of Single-Nucleotide Polymorphisms Clin. Chem., March 1, 2005; 51(3): 636 - 639. [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |